Denali Therapeutics Inc.
DNLINasdaq
$23.29
↑ +2.5%Jul 17 close · end-of-day
Price
1Y↑ +56.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$4.3B
Enterprise Value
$3.4B
P/E
—
P/S
—
P/B
4.7
EV/EBITDA
—
PEG
—
FCF Yield
-9.6%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$508.0M
Free Cash Flow (TTM)
-$419.2M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-54.9%
ROIC
—
Debt / Equity
—
Net Cash
$987.7M
Return 1Y
+60.3%
Company profile
Denali Therapeutics Inc. discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate product candidate. BIIB122/DNL151, a small molecule inhibitor, is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease.
- CEO
- Ryan J. Watts
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 430
- Headquarters
- California
- Website
- denalitherapeutics.com
Management & directors
- Schuth Alexander O.COFO and Secretary
- Watts Ryan J.President and CEO
- Ho CaroleChief Medical Officer
Roles derived from SEC Form 4 filings.
Earnings
DNLI Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.69↓ -11.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $335.7M | $48.7M | $108.5M | $330.5M | $0.00 | $0.00 |
| Gross profit | — | — | — | — | — | — |
| Operating income | $62.7M | -$295.8M | -$340.7M | -$196.7M | -$487.3M | -$555.3M |
| Net income | $71.1M | -$290.6M | -$326.0M | -$145.2M | -$422.8M | -$512.5M |
| Diluted EPS | $0.63 | -$2.39 | -$2.60 | -$1.06 | -$2.57 | -$2.97 |
| Operating cash flow | $416.2M | -$211.4M | -$244.7M | -$358.0M | -$347.7M | -$412.6M |
| Free cash flow | $413.1M | -$219.9M | -$262.5M | -$370.9M | -$363.6M | -$422.1M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | 18.7% | -607.8% | -314.2% | -59.5% | — | — |
| Net margin | 21.2% | -597.2% | -300.6% | -43.9% | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$116.6M | -$123.2M | -$129.8M | -$145.6M | -$135.0M | -$137.4M | -$137.4M | -$137.4M |
| Net income | -$99.0M | -$107.2M | -$114.8M | -$133.0M | -$124.1M | -$126.9M | -$128.5M | -$128.4M |
| Diluted EPS | -$0.59 | -$0.63 | -$0.67 | -$0.78 | -$0.72 | -$0.74 | -$0.73 | -$0.69 |
| Operating cash flow | -$91.2M | -$59.1M | -$83.7M | -$131.5M | -$75.3M | -$107.3M | -$98.5M | -$131.2M |
| Free cash flow | -$96.0M | -$63.0M | -$88.8M | -$136.5M | -$79.6M | -$108.7M | -$100.1M | -$133.7M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 20, 2026
Jul 13, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-03 | FLATLEY JAY T | Award | 6,408 | $0.00 | $0.00 | filing |
| 2026-06-03 | Klein Peter S | Award | 6,408 | $0.00 | $0.00 | filing |
| 2026-06-03 | Krognes Steve E. | Award | 6,408 | $0.00 | $0.00 | filing |
| 2026-06-03 | Schenkein David P | Award | 6,408 | $0.00 | $0.00 | filing |
| 2026-06-03 | Thornberry Nancy | Award | 6,408 | $0.00 | $0.00 | filing |
| 2026-06-03 | Van Hauwermeiren Timothy | Award | 6,408 | $0.00 | $0.00 | filing |
| 2026-06-03 | Cook Jennifer E. | Award | 6,408 | $0.00 | $0.00 | filing |
| 2026-06-03 | BAKER BROS. ADVISORS LP | Award | 6,408 | $0.00 | $0.00 | filing |
| 2026-06-03 | BAKER BROS. ADVISORS LP | Award | 6,408 | $0.00 | $0.00 | filing |
| 2026-01-06 | Watts Ryan J.· President and CEO | Sale | 35,198 | $16.50 | $580,767.00 | filing |
| 2026-01-06 | Schuth Alexander O.· COFO and Secretary | Sale | 17,218 | $16.50 | $284,097.00 | filing |
| 2026-01-03 | Schuth Alexander O.· COFO and Secretary | Award | 57,700 | $0.00 | $0.00 | filing |
| 2026-01-03 | Watts Ryan J.· President and CEO | Award | 78,960 | $0.00 | $0.00 | filing |
| 2025-11-04 | Van Hauwermeiren Timothy | Award | 10,632 | $0.00 | $0.00 | filing |
| 2025-09-03 | Watts Ryan J.· President and CEO | Gift | 50,000 | $0.00 | $0.00 | filing |
| 2025-08-13 | Ho Carole· Chief Medical Officer | Sale | 806 | $14.64 | $11,799.84 | filing |
| 2025-08-12 | Ho Carole· Chief Medical Officer | Sale | 2,937 | $13.58 | $39,884.46 | filing |
| 2025-08-12 | Schuth Alexander O.· COFO and Secretary | Sale | 2,937 | $13.58 | $39,884.46 | filing |
| 2025-08-05 | Ho Carole· Chief Medical Officer | Option exercise | 44,655 | $0.68 | $30,365.40 | filing |
| 2025-07-09 | Watts Ryan J.· President and CEO | Sale | 495,282 | $15.00 | $7.4M | filing |
| 2025-07-09 | Watts Ryan J.· President and CEO | Option exercise | 455,282 | $0.68 | $309,591.76 | filing |
| 2025-07-09 | Watts Ryan J.· President and CEO | Option exercise | 40,000 | $5.28 | $211,200.00 | filing |
Latest 22 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.